NASDAQ:APTO
Aptose Biosciences Stock News
$1.23
+0 (+0%)
At Close: May 09, 2024
Aptose Biosciences Establishes New At-The-Market Facility
08:17pm, Tuesday, 05'th May 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer,
Aptose Reports Results for the First Quarter 2020
08:00pm, Tuesday, 05'th May 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer,
Aptose Biosciences, Inc. to Host Earnings Call
07:00pm, Tuesday, 05'th May 2020
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 P
The Most Exciting Mental Health Breakthrough Of The Decade?
12:00am, Monday, 04'th May 2020One Biotech Stock For 2020
11:30pm, Sunday, 03'rd May 2020
FDA has just fast-tracked research on an exciting new mental health treatment, and one small company is making moves to secure its place as an early mover in this revolution
Canaccord Genuity Remains a Buy on Aptose Biosciences (APTO)
10:08am, Tuesday, 28'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTO) yesterday and set a price target of $13.00. The company's
Why Aptose Biosciences Stock Sank Today
07:29pm, Monday, 27'th Apr 2020
Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.
Aptose Highlights Presentation Of Prelim. Clinical Data On CG-806 At AACR Virtual Meeting
01:09pm, Monday, 27'th Apr 2020Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
01:00pm, Monday, 27'th Apr 2020
SAN DIEGO and TORONTO, April 27, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting
11:30am, Friday, 24'th Apr 2020
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer,
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting
12:00am, Friday, 24'th Apr 2020Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020
11:30am, Tuesday, 21'st Apr 2020
SAN DIEGO and TORONTO, April 21, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.
Aptose to Release First Quarter Ended March '–, —…—… Financial Results and Hold ...
12:00am, Tuesday, 21'st Apr 2020Aptose Biosciences (TSE:APS) Reaches New 1-Year High at $12.24
09:18am, Saturday, 18'th Apr 2020
Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) hit a new 52-week high on Thursday . The company traded as high as C$12.24 and last traded at C$11.57, with a volume of 82516 shares changing hands. The
